Key Performance
More- Earnings Score: N/A
- Momentum Score: 74
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Cytek Biosciences unveiled its new 7-laser Cytek Borealis full spectrum flow cytometer featuring Deep Ultraviolet and Infrared capabilities with 120 detectors, enabling high-resolution 60-color panels. The company also announced automation-ready configurations for the Cytek Aurora Evo system designed to integrate with robotic plate handling and third-party scheduling platforms, targeting biopharma and CRO organizations.
06/02/2026, 5:00 PM • GlobeNewswire
Cytek Biosciences marks the one-year anniversary of its 8,500-square-foot Singapore facility, which has enhanced manufacturing capacity, regional service capabilities, and supply chain resilience. The facility serves as a strategic hub for Asia-Pacific operations and supports the company's growth in cell analysis solutions driven by increasing global demand in immunology, immuno-oncology, and cancer research.
03/09/2026, 5:00 PM • GlobeNewswire
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Cytek Biosciences announced preliminary Q4 2025 revenue of approximately $62 million, representing 8% year-over-year growth and 19% sequential growth. Full year 2025 revenue is expected to be approximately $201 million. The company highlighted strong growth in Services, Reagents, and Asia Pacific instrument revenue, along with improved instrument sales in the US and EMEA regions, particularly a return to positive growth in EMEA.
01/12/2026, 5:00 AM • GlobeNewswire
TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026
Cytek Biosciences was recognized by TIME and Statista as one of America's top-performing publicly listed companies, highlighting its exceptional growth, financial stability, and innovative cell analysis solutions.
11/12/2025, 5:00 PM • GlobeNewswire
Cytek Biosciences' Muse Micro cell analyzer won the 2025 BioTech Breakthrough Award for Drug Discovery Solution of the Year, highlighting its innovative approach to making cell analysis more accessible and cost-effective for laboratories.
11/06/2025, 5:00 PM • GlobeNewswire
Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
Cytek Biosciences is launching a two-part research support initiative to make cell analysis more accessible, including awarding a flow cytometer and planning a research grant program in collaboration with ISAC to support scientific research globally.
10/29/2025, 5:00 PM • GlobeNewswire
Cytek Biosciences relocates and expands its European headquarters in Amsterdam, increasing its facility footprint by over 40% and establishing a dedicated customer service and training center to strengthen its presence in the EMEA region.
10/15/2025, 5:00 PM • GlobeNewswire
Cytek Biosciences will showcase its advanced cell analysis solutions at ESCCA and ICCS conferences, highlighting its Full Spectrum Profiling technology and its potential to transform cell biology research through high-parameter spectral flow cytometry.
09/10/2025, 5:00 PM • GlobeNewswire
Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change
MDxHealth appointed Michael Holder to its Board of Directors as Audit Committee Chair, replacing Regine Slagmulder. CFO Ron Kalfus is resigning, with Scott McMahan assuming interim CFO responsibilities.
07/03/2025, 1:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.